Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	September 8, 2022
Length of Meeting:	1 hour and 26 minutes
Location of Meeting:	DMAS Board Room 102

Members Present:
John Morgan, MD, Chief Clinical Innovation Officer, Chair
Rachel Cain, PharmD
Elizabeth Gaughan, MD
Kristi Fowler, RPh
Matthew Estes, PharmD
Melissa Chouinard, MD
Wendy Nash, PharmD
Denese Gomes, NP
Denise Lowe, PharmD

Members Not Present:
Randy Ferrance, MD
Kathryn Reid, PhD
Michele Thomas, PharmD
Seth Brant, MD

DMAS Attendees:
MaryAnn McNeil, RPh, Pharmacy Manager
Nettie Emmelhainz, PharmD, Senior Pharmacy Policy and Data Analyst
JoeMichael Fusco, PharmD, Common Core Formulary Pharmacist
Kiara Jasper, MHA, CPhT, Pharmacy Systems Administrator

Contractors:
Nancy Eldin, PharmD, Pharmacist Account Executive, Magellan Health Services
Jeni Hodzic, CPhT, Senior Account Management Specialist, Magellan Health Services

Visitors:
Keri Smith
David Roy
Tom Lennox
Niki Hwang
Mark Stephens

Howard Becker
John Minneci

Call to Order and Introductions

Dr. John Morgan welcomed and thanked everyone for attending the DUR meeting.

Dr. Morgan called the meeting to order at 1:07 pm.

Minutes – June 2, 2022

Kristi Fowler motioned to approve the June 2, 2022 meeting minutes as submitted. Dr. Melissa Chouinard seconded the motion.

New Drugs

The DUR Board reviewed Camzyos™ (mavacamten), Vijoice® (alpelisib) and Vonjo™ (pacritinib). The Impact Reports and the report for the utilization of these 3 new DUR drugs for FFS and MCOs were reviewed.

The DUR Board discussed the service authorization (SA) criteria for Vijoice®. After much discussion by the board, Denese Gomes motioned to accept the service authorization criteria with the following changes; revise question number 6 to “Has the member had a baseline fasting plasma glucose and HbA1c performed and are optimized as able?”, revise question number 8 to “Have individual members of reproductive potential and individual members with individual partners of reproductive potential been counselled on the use of effective contraception during alpelisib treatment and for 1 week after the last dose?” and revise question number 12 to “Does the member have evidence of clinical benefit?”. Dr. Morgan seconded the motion.

The DUR Board discussed the SA criteria for Vonjo™. Vonjo™ has been added to the DUR Oral Oncology – Hematologic Cancers and Other Neoplasm Drugs SA criteria fax form. Dr. Chouinard motioned to accept the SA criteria as is. Dr. Rachel Cain seconded the motion.

MRx Pipeline and DUR Quarterly Newsletter- The July 2022 MRx Pipeline Report and the June 2022 DUR Quarterly Newsletter were available on the DUR Webportal for review.

Topics for Discussion

Antidepressant Medications in Children – The DUR Board reviewed Antidepressant Medications in Children reports for FFS and MCOs. There was discussion around suicidal ideations in the pediatric population and questions on how that is monitored and managed. DMAS will follow-up with Behavioral Health. This new report will be reviewed twice a year by the DUR Board.

Mood Stabilizer Medications in Children – The DUR Board reviewed Mood Stabilizer Medications in Children reports for FFS and MCOs. This new report will be reviewed twice a year by the DUR Board.

Synagis® – The DUR Board reviewed the Synagis® Utilization Report for last season. The upcoming Synagis® season will be from October 1, 2022 through March 31, 2023 with any early requests being reviewed by DMAS on a case-by-case basis. Ms. Fowler motioned to accept the SA Synagis® criteria with the following changes; remove the statement "No dose may be given after March 31." on page 4 of the fax form under the "NOTE" section. Dr. Morgan seconded the motion.

Reports

ProDUR

The DUR Board reviewed the ProDUR reports including the new version of the ProDUR Top Encounters by Problem Type Report to show only the severity level 1 ProDUR edits.

RetroDUR

I. Recent RetroDUR Activity

The DUR Board reviewed the Recent RetroDUR Activity reports.

DMAS will be sending another letter in October 2022 to inform prescribers that they must be enrolled as a Virginia Medicaid provider in order to prescribe medications to Virginia Medicaid members.

II. RetroDUR Criteria Estimates

The DUR Board reviewed the Criteria Exception Estimates Reports. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment

Amount for Fee-For-Service (FFS) and each individual Managed Care Organization (MCO) plan.

Utilization Analysis

The DUR Board reviewed the Utilization Analysis reports. These reports have been updated to exclude the medical claims and only include pharmacy claims.

Next DUR Meeting

December 15, 2022

Dr. Chouinard motioned to adjourn the meeting. Dr. Morgan seconded the motion.
Meeting adjourned at 2:33 pm.